NCT02991118View on ClinicalTrials.gov

Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk

PHASE3CompletedINTERVENTIONAL
Enrollment

779

Participants

Timeline

Start Date

November 18, 2016

Primary Completion Date

August 22, 2018

Study Completion Date

August 22, 2018

Conditions
HypercholesterolemiaAtherosclerotic Cardiovascular Disease
Interventions
DRUG

bempedoic acid

bempedoic acid 180 mg tablet taken orally, once daily. Patients remain on ongoing lipid-modifying therapy (not study provided)

DRUG

placebo

Matching placebo tablet taken orally, once daily. Patients remain on ongoing lipid-modifying therapy (not study provided)

Trial Locations (2)

Unknown

Clearwater

Georgetown

Sponsors
All Listed Sponsors
lead

Esperion Therapeutics, Inc.

INDUSTRY